Synvivia, Inc.

Brief Description

Synvivia is a synthetic biology company that optimizes cell behavior for gene therapy manufacturing, providing a practical solution for genetically encoded biocontainment. The company is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory.

The company's technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine. Synvivia has exclusive license to the intellectual property in all fields of use. Backed by Y Combinator, the National Institutes of Health, and industrial partnerships.

Synvivia founder and CEO Gabriel Lopez co-invented the company's foundational technology as a UC Berkeley Bioengineering and Biomedical Engineering PhD student. He expanded on his doctoral work as a postdoc in the lab of UC Berkeley Professor of Entomology John Anderson, developing new protein engineering architectures and workflows.

Inventors

Gabriel Lopez, John Anderson